• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶囊药物装置:眼部给药的新方法。

The capsule drug device: novel approach for drug delivery to the eye.

作者信息

Molokhia Sarah A, Sant Himanshu, Simonis Jacquelyn, Bishop C J, Burr R M, Gale Bruce K, Ambati Balamurali K

机构信息

Department of Ophthalmology, Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA.

出版信息

Vision Res. 2010 Mar 31;50(7):680-5. doi: 10.1016/j.visres.2009.10.013. Epub 2009 Oct 23.

DOI:10.1016/j.visres.2009.10.013
PMID:19854210
Abstract

Treatment of age-macular degeneration requires monthly intravitreal injections, which are costly and have serious risks. The objective of this study was to develop a novel intraocular implant for drug delivery. The capsule drug ring is a reservoir inserted in the lens capsule during cataract surgery, refillable and capable of delivering multiple drugs. Avastin was the drug of interest in this study. Prototypes were manufactured using polymethylmethacrylate sheets as the reservoir material, a semi-permeable membrane for controlled delivery and silicone check valves for refilling. The device showed near zero-order release kinetics and Avastin stability was investigated with accelerated temperature studies.

摘要

年龄相关性黄斑变性的治疗需要每月进行玻璃体内注射,这种治疗成本高昂且存在严重风险。本研究的目的是开发一种新型的眼内药物递送植入物。胶囊药物环是一种在白内障手术期间插入晶状体囊袋的储库,可再填充且能够递送多种药物。阿瓦斯汀是本研究中感兴趣的药物。使用聚甲基丙烯酸甲酯片材作为储库材料、用于控释的半透膜和用于再填充的硅胶止回阀制造了原型。该装置显示出接近零级的释放动力学,并通过加速温度研究对阿瓦斯汀的稳定性进行了研究。

相似文献

1
The capsule drug device: novel approach for drug delivery to the eye.胶囊药物装置:眼部给药的新方法。
Vision Res. 2010 Mar 31;50(7):680-5. doi: 10.1016/j.visres.2009.10.013. Epub 2009 Oct 23.
2
Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).回复:玻璃体内注射贝伐单抗(阿瓦斯汀)后眼压的变化
Retina. 2008 Apr;28(4):667; author reply 667-8. doi: 10.1097/IAE.0b013e31816577e1.
3
Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性:连续三个月每月注射的疗效
Am J Ophthalmol. 2008 Jul;146(1):91-5. doi: 10.1016/j.ajo.2008.03.014. Epub 2008 May 2.
4
Quiescent posterior capsule trauma after intravitreal injection: implications for the cataract surgeon.
J Cataract Refract Surg. 2011 Jul;37(7):1364. doi: 10.1016/j.jcrs.2011.04.016.
5
Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration.玻璃体腔内注射阿瓦斯汀治疗年龄相关性黄斑变性后出现的查尔斯·博内综合征(视幻觉)
Am J Ophthalmol. 2007 Aug;144(2):330; author reply 330-1. doi: 10.1016/j.ajo.2007.04.002.
6
Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?玻璃体内注射血管内皮生长因子(VEGF)抑制剂:阿瓦斯汀(Avastin)能否作为雷珠单抗(Lucentis)的通用替代品?
Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. doi: 10.1111/j.1600-0420.2006.00869.x.
7
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性中心凹下脉络膜新生血管:泛美视网膜协作研究组12个月随访结果
Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.
8
[New drug treatment for age-related macular degeneration].[年龄相关性黄斑变性的新药治疗]
Laeknabladid. 2007 Apr;93(4):299-301.
9
How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis?
Br J Ophthalmol. 2008 Sep;92(9):1298-9. doi: 10.1136/bjo.2008.138396.
10
Intravitreal bevacizumab.玻璃体内注射贝伐单抗。
Ophthalmology. 2007 Feb;114(2):400; author reply 400-1. doi: 10.1016/j.ophtha.2006.10.002.

引用本文的文献

1
Progress in Ocular Drug Delivery: Challenges and Constraints.眼部药物递送的进展:挑战与限制
Handb Exp Pharmacol. 2024;284:267-288. doi: 10.1007/164_2023_693.
2
Nanocarriers for ocular drug delivery: Recent advances and future opportunities.用于眼部药物递送的纳米载体:最新进展与未来机遇。
Indian J Ophthalmol. 2023 Jun;71(6):2355-2366. doi: 10.4103/ijo.IJO_1893_22.
3
In vitro dissolution testing models of ocular implants for posterior segment drug delivery.用于后段药物递送的眼部植入物的体外溶解测试模型。
Drug Deliv Transl Res. 2022 Jun;12(6):1355-1375. doi: 10.1007/s13346-021-01043-z. Epub 2021 Aug 11.
4
Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials.用于治疗眼内疾病的聚合物植入物:可生物降解和不可生物降解材料的发展趋势
Pharmaceutics. 2021 May 12;13(5):701. doi: 10.3390/pharmaceutics13050701.
5
Fouling in ocular devices: implications for drug delivery, bioactive surface immobilization, and biomaterial design.眼用器械污染:对药物输送、生物活性表面固定化和生物材料设计的影响。
Drug Deliv Transl Res. 2021 Oct;11(5):1903-1923. doi: 10.1007/s13346-020-00879-1. Epub 2021 Jan 16.
6
Therapeutic Ophthalmic Lenses: A Review.治疗性眼科镜片:综述
Pharmaceutics. 2020 Dec 28;13(1):36. doi: 10.3390/pharmaceutics13010036.
7
The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer.非肌层浸润性膀胱癌膀胱内药物递送的未来
Bladder Cancer. 2016 Jul 27;2(3):285-292. doi: 10.3233/BLC-160056.
8
Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications.用于被动药物递送应用的微流体通道扩散特性研究。
J Drug Deliv. 2016;2016:7913616. doi: 10.1155/2016/7913616. Epub 2016 May 26.
9
A flexible device for ocular iontophoretic drug delivery.一种用于眼部离子电渗药物递送的柔性装置。
Biomicrofluidics. 2016 Feb 24;10(1):011911. doi: 10.1063/1.4942516. eCollection 2016 Jan.
10
Single compartment drug delivery.单室药物递送。
J Control Release. 2014 Sep 28;190:157-71. doi: 10.1016/j.jconrel.2014.04.049. Epub 2014 May 4.